OR WAIT null SECS
February 04, 2022
Pharming Group has announced positive results from the Phase II/III study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
The UK’s NICE issued a Final Appraisal Document recommending marketing authorization for AstraZeneca’s chronic kidney disease treatment, Forxiga (dapagliflozin).
February 02, 2022
Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.
Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.
As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.
February 01, 2022
Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.
Recipharm will build up its biologics service offering with the acquisition of GenIbet.
January 31, 2022
Metagenomi has successfully raised $175 million for use toward its research pipeline.
Both Pfizer and Moderna have started clinical trials for their respective Omicron COVID-19 variant vaccine.
The draft PREVENT Pandemic Act aims to secure supply chains, expand health data collection, and support access to vital medical products